Blair, Paul W.
Brandsma, Joost
Chenoweth, Josh
Richard, Stephanie A.
Epsi, Nusrat J.
Mehta, Rittal
Striegel, Deborah
Clemens, Emily G.
Alharthi, Sultanah
Lindholm, David A.
Maves, Ryan C.
Larson, Derek T.
Mende, Katrin
Colombo, Rhonda E.
Ganesan, Anuradha
Lalani, Tahaniyat
Colombo, Christopher J.
Malloy, Allison A.
Snow, Andrew L.
Schully, Kevin L.
Lanteri, Charlotte
Simons, Mark P.
Dumler, John S.
Tribble, David
Burgess, Timothy
Pollett, Simon
Agan, Brian K.
Clark, Danielle V.
Cowden, J.
Darling, M.
Merritt, T.
Wellington, T.
Rutt, A.
Conlon, C.
Faestel, P.
Mount, C.
Smith, A.
Tant, R.
Warkentien, T.
Berjohn, C.
Utz, G.
Madar, C.
Uyehara, C.
Chung, K.
English, C.
Fox, C.
Grother, M.
Hickey, P.
Laing, E.
Livezey, J.
Parmelee, E.
Rozman, J.
Sanchez, M.
Scher, A.
Chao, T.
Chapleau, R.
Fries, A.
Reynolds, K.
Hostler, D.
Hostler, J.
Lago, K.
Maldonado, C.
Hunter, T.
Mody, R.
Wayman, M.
Huprikar, N.
,
Funding for this research was provided by:
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (W911QY-20-9-0004)
National Institute of Allergy and Infectious Diseases, National Institutes of Health (Y1-AI-5072)
Defense Health Program, U.S. DoD (HU0001190002)
Defense Health Agency, U.S. DoD (HU00012020070, W911QY-20-9-0006)
Article History
Received: 14 March 2022
Accepted: 22 December 2022
First Online: 28 December 2022
Competing interests
: S. D. P., M.P.S., T. H. B, and D.R.T. report that the Uniformed Services University (USU) Infectious Diseases Clinical Research Program (IDCRP), a US Department of Defense institution, and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc (HJF) were funded under a Cooperative Research and Development Agreement to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was funded by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase III vaccine trial sponsored by AstraZeneca. Both of these trials were part of the US Government COVID-19 response. Neither is related to the work presented here. All other authors declare no competing interests.